
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



03 FEB 24 PH 3: (

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

	Registrant Name			
	The Duberstein Group, Inc.			
	Registrant Address	fferent than previously reported ve, NW Ste 500 State/Zip (or Country)	DC 20037 US	Α
	Principal Place of Business (if different			
υ.	City	State/Zip (or Country)	·	
4.	Contact Name John W. Angus, III	Telephone E-ma	iil (optional)	5. Senate ID # 12675-24
7.	Client Name Self			6. House ID#
	American Association of Hea	lth Plans		31811010
€.	Check if this filing amends a particle of the check if this is a Termination		nis report 🛚	11. No Lobby
9. 10.		reviously filed version of the Report	on Date er Line 12 OR Line 13	11. No Lobby
9. 10.	Check if this is a Termination	reviously filed version of the Report >>> Termination SES - Complete Either	on Date er Line 12 OR Line 13	13. Organizations
9. 10. II	Check if this is a Termination	reviously filed version of the Report >> Termination SES - Complete Either Firms	on Date er Line 12 OR Line 13	
9. 10. II	Check if this is a Termination NCOME OR EXPEN 12. Lobbying NCOME relating to lobbying ac	reviously filed version of the Report >> Termination SES - Complete Either Firms	on Date er Line 12 OR Line 13 EXPENSES relating to	13. Organizations
9. 10. If po	Check if this is a Termination NCOME OR EXPEN 12. Lobbying NCOME relating to lobbying accertiod was:	reviously filed version of the Report >> Termination SES - Complete Either SES - Complete Either	er Line 12 OR Line 13 EXPENSES relating to period were: Less than \$10,000	13. Organizations
9. 10. III po	Check if this is a Termination NCOME OR EXPEN 12. Lobbying NCOME relating to lobbying accerted was: ess than \$10,000 10,000 or more x >> \$	reviously filed version of the Report >> Termination SES - Complete Either SES - Complete Either	er Line 12 OR Line 13 EXPENSES relating to period were: Less than \$10,000 □ \$10,000 or more □	13. Organizations lobbying activities for this rep
9. 10. III po L \$	Check if this is a Termination Incomit on Expension 12. Lobbying according to lobbying according was: The state of the st	Report >> Termination SES - Complete Either g Firms ctivities for this reporting \$180,000.00 Income (nearest \$20,000) unded to the nearest acome from the client gistrant by any other entity	EXPENSES relating to period were: Less than \$10,000 \$10,000 or more 14. REPORTING ME accounting method. See	13. Organizations lobbying activities for this rep >> \$ Expenses (nearest \$2 THOD. Check box to indicate instructions for description of the second amounts using LDA definitions).
9. 10. III po L \$	Check if this is a Termination NCOME OR EXPEN 12. Lobbying NCOME relating to lobbying accerted was: ess than \$10,000 10,000 or more >>\$ - rovide a good faith estimate, rov 20,000 of all lobbying related in	Report >> Termination SES - Complete Either g Firms ctivities for this reporting \$180,000.00 Income (nearest \$20,000) unded to the nearest acome from the client gistrant by any other entity	EXPENSES relating to period were: Less than \$10,000 \$10,000 or more 14. REPORTING ME accounting method. See Method A. Reporti	13. Organizations lobbying activities for this rep >> \$ Expenses (nearest \$2 THOD. Check box to indicate instructions for description or

a:		Date	2/14/2003	
Signature			_	
Printed Name and Title	John W. Angus, III - Senior Vice President & GC	···		_ P

berstein Group, Inc.	
an Association of Health Plans	
Select as many codes as necessary to reflect alf of the client during the reporting period. ttach additional page(s) as needed.	the general issue areas in which the registrant Using a separate page for each code, provide
e <u>HCR</u> (one per page)	
iness Health Fairness Act of 2001, Assn. hon Fairness Act of 2001, Tort reform a Patient Protection Act, Patients' bill of rade Promotion and Drug Eradication Acter Antitrust Improvements Act of 2002, Actent Equitable Treatment Act of 2002, Mail Mail Accessible, Low Cost, Timely Health Ifety Improvement Act of 2002, Medical education Acter Security Act of 2002, Healthcare	rights ct, Healthcare Antitrust Iental health n Care (HEALTH) Act of 2002, Medical malp rrors to provide for the improvement of patient saf
and Federal agencies contacted	☐ Check if None
hual who acted as a lobbyist in this issue area	ı
Cove	
Cove	ered Official Position (if applicable)
Cove	ered Official Position (if applicable)
	ered Official Position (it applicable)
	ered Official Position (it applicable)
	ered Official Position (if applicable)
4.	ered Official Position (it applicable)
4.	ered Official Position (it applicable)
4.	ered Official Position (it applicable)
	alf of the client during the reporting period. Itach additional page(s) as needed. Le HCR (one per page) Les iness Health Fairness Act of 2001, Assn. In on Fairness Act of 2001, Tort reform a Patient Protection Act, Patients' bill of rade Promotion and Drug Eradication Act are Antitrust Improvements Act of 2002, Act alth Equitable Treatment Act of 2002, Medical electry Improvement Act of 2002, Medical electrical Security Act of 2002, Healthcare at title IX of the Public Health Service Act of events that adversely effect patient safe and Federal agencies contacted

G:		Date 2/14/2003	
Signature			
Printed Name and Title	John W. Angus, III - Senior Vice President & GC		F

00030153121

Registrant Name: The Duberstein Group, Inc.

Client Name: American Association of Health Plans

Item	Description	Data
16	Lobbying Issues	H.R.5716, Mental Health Parity Reauthorization Act of 2002, Mental health
16	Lobbying Issues	H.R.602, Genetic Nondiscrimination in Health Insurance and Employment Ac Privacy
16	Lobbying Issues	H.R.831, Long-Term Care and Retirement Security Act of 2001, Long-term c
16	Lobbying Issues	S.1052, Bipartisan Patient Protection Act, Patients' bill of rights
16	Lobbying Issues	S.1712, Class Action Fairness Act of 2001, Tort reform
16	Lobbying Issues	S.1995, Genetic Information Nondiscrimination Act of 2002, Privacy
16	Lobbying Issues	S.2590, Patient Safety and Quality Improvement Act, Privacy
16	Lobbying Issues	S.3029, Patient Safety Improvement and Medical Injury Reduction Act, Priva
16	Lobbying Issues	S.543, Mental Health Equitable Treatment Act of 2001, Mental health
16	Lobbying Issues	S.710, Eliminate Colorectal Cancer Act of 2001, Healthcare
16	Lobbying Issues	S.754. Drug Competition Act of 2001, Prescription drugs
16	Lobbying Issues	S.812, Greater Access to Affordable Pharmaceuticals Act of 2001, Prescription
16	Lobbying Issues	S.858, Small Business Health Fairness Act of 2001, Assn. health plans

Registrant Name: The Duberstein Group, Inc.	
Client Name: <u>American Association of Health Plans</u>	
LOBBYING ACTIVITY. Select as many codes as necessar engaged in lobbying on behalf of the client during the reporti information as requested. Attach additional page(s) as needed	ng period. Using a separate page for each code, provide
15. General issue area code <u>INS</u> (one per page)	
16. Specific Lebbying issues OTHER CONGRESSIONAL ACTIONS: Legislativ	e proposals re health terrorism insurance
17. House(s) of Congress and Federal agencies contacted House of Representatives	☐ Check if None
18. Name of each individual who acted as a lobbyist in this	s issue area
Name	Covered Ófficial Position (if applicable)
Angus, III, John W.	
Berman, Michael S.	
Champlin, Steven M.	
Duberstein, Kenneth M.	
Gandy, Henry M.	
Meyer, Daniel	
19. Interest of each foreign entity in the specific issues lis	ted on line 16 above Marcheck if None

Signature		Date	
Printed Name and Title	John W. Angus, III - Senior Vice President & GC	Pa	

00030153123

Regis	strant Name:	The Duberstein Group, Inc.	
Clien	it Name:	American Association of Health Plan	is
engag	ged in lobbyir	TVITY. Select as many codes as necessing on behalf of the client during the reportested. Attach additional page(s) as need	ary to reflect the general issue areas in which the registrant range period. Using a separate page for each code, provide ed.
15.	General issue	area code MMM (one per pag	e)
	H.R.2630, F: H.R.2836, M H.R.2980, M H.R.3584, M H.R.4954, M prescription H.R.4961, T H.R.4984, T	edicare Equity and Access Act of 200 mily Care Act of 2001, Medicaid edicare+Choice Equity and Access Actedicare+Choice Stabilization and Impledicare+Choice Improvement and Statedicare Modernization and Prescript drug benefit	et of 2001, Medicare + Choice Provement Act of 2001, Medicare + Choice Publication Act of 2001, Medicare + Choice Publication Act of 2001, Medicare + Choice Publication Drug Act of 2002, Medicare+Choice funding; Medicar Publication on the Future of Medicaid., Medicaid Publication or the Future of Medicare prescription drug benefits
17.		Congress and Federal agencies contacted presentatives House	☐ Check if None
18.	Name of eac	h individual who acted as a lobbyist in th	nis issue area
	Name		Covered Official Position (if applicable)
	Angus, III,	John W.	
	Berman, M	ichael S.	
	Champlin,	Steven M.	
	Duberstein	Kenneth M.	
	Gandy, He	nry M.	
	Meyer, Da	niel	
19.	Interest of e	ach foreign entity in the specific issues l	isted on line 16 above Check if None

Filing #86f53ec0-cddf-4137-8068-71d6b9f1951b - Page 9 of 12

Signature Date 2/14/2003

Printed Name and Title John W. Angus, III - Senior Vice President & GC

P:

Registrant Name: The Duberstein Group, Inc.

Client Name:

American Association of Health Plans

Item	Description	Data
16	Lobbying Issues	H.R.4985, To amend title XVIII of the Social Security Act to revitalize the MedicareChoice Program, establish a MedicareChoice competition program, to improve payments to hospitals and other providers under part A of the
16	Lobbying Issues	Medicare Program., MedicareChoice funding H.R.5019, To amend titles XVIII and XIX of the Social Security Act to provid a voluntary Medicare prescription medicine benefit, to provide greater access affordable pharmaceuticals, to revise and improve payments to providers of services under the Medicar, Medicare prescription drug benefit
16	Lobbying Issues	H.R.5727, Medicare Improvements for Special Needs Beneficiaries Act of 200 Medicare Choice
16	Lobbying Issues	H.R.573, Teacher Technology Training Act, Medicare reform
16	Lobbying Issues	H.R.600, Dylan Lee James Act Family Opportunity Act of 2001, Medicaid
16	Lobbying Issues	S.1135, Medicare Reform Act of 2001, Medicare prescription drug benefit
16	Lobbying Issues	S.1224, Medicare Cost Contract Extension Act of 2001, Medicare reform
16	Lobbying Issues	S.1244, FamilyCare Act of 2001, Medicaid
16	Lobbying Issues	S.1317, MedicareChoice Equity and Access Act of 2001, Medicare Choice
16	Lobbying Issues	S.1851, MedicareChoice Consumer Protection Act of 2001, Medicare Choice
16	Lobbying Issues	S.2570, A bill to temporarily increase the Federal medical assistance percenta for the medicaid program, and for other purposes., Medicaid
16	Lobbying Issues	S.2625, Medicare Outpatient Prescription Drug Act of 2002, MedicareChoice funding; Medicare prescription drug benefit
16	Lobbying Issues	S.2729, 21st Century Medicare Act, Medicare prescription drug benefit
16	Lobbying Issues	S.2736, Medicare Rx Drug Discount and Security Act of 2002, Medicare
		prescription drug benefit
16	Lobbying Issues	S.3018, Beneficiary Access to Care and Medicare Equity Act of 2002, Medicare Choice funding
16	Lobbying Issues	S.321, Dylan Lee James Act Family Opportunity Act of 2001, Medicaid
16	Lobbying Issues	
16	Lobbying Issues	